Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionDakota Wealth Management
Latest Disclosed Ownership2,829 shares
Latest Disclosed Value $ 1,263,263
Dakota Wealth Management ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 7, 2026 - Dakota Wealth Management filed a 13F-HR form disclosing ownership of 2,829 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $1,263,262 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 13, 2026 disclosing 2,623 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 7.85% during the quarter. The current value of the position is $1,264,082 USD.

Dakota Wealth Management has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-07 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,829 206 7.85 1,263 6.22 0.0273
2026-01-13 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,623 43 1.67 1,189 17.72 0.0211
2025-11-10 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,580 -430 -14.29 1,010 -24.63 0.0204
2025-07-16 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,010 -7,137 -70.34 1,340 -72.76 0.0282
2025-05-02 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 10,147 2,739 36.97 4,919 64.90 0.1151
2025-01-17 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,408 -26,985 -78.46 2,983 -81.35 0.0686
2024-10-23 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,393 4,042 13.32 15,995 12.43 0.3614
2024-07-22 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 30,351 -2,031 -6.27 14,226 5.10 0.3343
2024-04-24 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 32,382 9,240 39.93 13,536 43.76 0.3361
2024-01-30 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 23,142 20,427 752.38 9,416 897.46 0.3658
2023-10-24 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,715 802 41.92 944 40.27 0.0417
2023-07-31 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,913 319 20.01 673 34.06 0.0317
2023-04-14 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,594 -247 -13.42 502 -5.46 0.0335
2023-02-08 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,841 -475 -20.51 532 -20.75 0.0377
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,316 174 8.12 670 10.93 0.0542
2022-08-05 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,142 -139 -6.09 604 1.51 0.0556
2022-05-13 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,281 281 14.05 595 35.54 0.0483
2022-02-10 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 439 20.94 0.0463
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 363 -9.93 0.0418
2021-08-02 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 403 -6.28 0.0480
2021-05-10 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 -23 -1.14 430 -10.04 0.0564
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,023 8 0.40 478 -12.77 0.0622
2020-11-04 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,015 -9,531 -82.55 548 -83.65 0.0864
2020-08-07 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 11,546 9,546 477.30 3,352 604.20 0.5735
2020-04-29 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 476 8.68 0.1039
2020-02-06 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 438 29.20 0.0702
2019-11-14 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 339 -7.63 0.0584
2019-08-07 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 367 -0.27 0.0702
2019-04-29 2019-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 368 -4.42 0.0732
2019-01-22 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 385 0.00 0.0872
2018-11-07 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 385 13.24 0.0865
2018-08-09 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 340 4.29 0.0945
2018-04-10 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 326 8.67 0.1681
2018-01-16 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 300 -1.32 0.1590
2017-10-16 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 304 17.83 0.1646
2017-07-10 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 258 17.81 0.1426
2017-04-12 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 2,000 219 0.1279
2016-05-16 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -2,000 -100.00 0 -100.00
2016-01-12 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 252 21.15 0.1708
2015-10-16 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 208 -15.79 0.1425
2015-07-13 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 247 4.66 0.1492
2015-04-13 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 0 0.00 236 -0.84 0.1403
2015-01-26 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,000 2,000 238 0.1488
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2022-11-10 2022-09-30 13F VERTEX PHARMACEUTICALS COM Call 2,895 -48.63 n/a n/a n/a
2022-08-05 2022-06-30 13F VERTEX PHARMACEUTICALS COM Call 5,636 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.